Floatz logo

Paclitaxel Poliglumex

Ovarian Transitional Cell Carcinoma

GOG FoundationPhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Ovarian Transitional Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB

View all 20 →

Same molecule, other indications

Paclitaxel Poliglumex is also rated in:

Primary Peritoneal CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Malignant Ovarian Mixed Epithelial TumorDormant
B
Indicative ·
56 / 100
View asset →
Ovarian Brenner TumorDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →